BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GENFIT Corp. (ALGFT) Signs Drug Deal with Sanofi-Aventis (France) (SASY.PA), Shares Surge; Milestone Fees Could be as Much as $54.5 Million


3/17/2011 7:08:46 AM

Lille, France, and Cambridge, Mass., March 17th, 2011 - GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focused on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it has signed a new contract with SANOFI-AVENTIS for the research and development of new drugs for the treatment of metabolic disorders.

Through this agreement, SANOFI-AVENTIS obtains the exclusive worldwide rights to develop and commercialize molecules resulting from the research collaboration. In exchange, GENFIT will receive annual payments and could receive additional milestone payments according to the progress of the development, registration, and commercialization of the resulting products.

Within this research program, GENFIT will collaborate with SANOFI-AVENTIS to identify molecules that aim to correct the mitochondrial dysfunction associated with certain pathologies including metabolic diseases. Indeed, based on clinical observations, the cellular mechanisms that regulate energy production under normal conditions, and their capacity to adapt to stress, may have therapeutic potential in such disorders.

Jean-François Mouney, Chairman of GENFIT's Management Board, declared: "We are very pleased to pursue our alliance with SANOFI-AVENTIS after more than 10 years of collaboration. We are particularly proud of the new risk-sharing aspect of the collaboration, demonstrating the strong commitment of both parties. The combination of GENFIT's expertise and technological platforms, together with the experience of SANOFI-AVENTIS in R&D and drug commercialization, offers extremely interesting perspectives for our collaborative research program."

According to the terms of the alliance, GENFIT will receive annual payments to fund research within the collaboration, in addition to milestone payments according to the progress of preclinical and clinical development, and the subsequent registration and commercialization of resulting products. The total of these milestone payments could reach $54.5 million (39 million Euros). GENFIT will also receive royalties from future sales of products developed by SANOFI-AVENTIS that result from the collaboration.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases.). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER, .), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II. With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext(TM) Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com



Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES